AGP Executive Report
Last update: 10 hours agoHepatitis B Trial: A proposed study involving 14,000 newborns in Guinea-Bissau is back in focus after Danish researchers defended a revised plan to compare a birth-dose vaccine with the country’s current schedule, which starts at six weeks. Half the babies would not receive the shot at birth. Guinea-Bissau’s health minister says the government has not authorized the trial, while researchers say ethics committees approved the updated protocol. Why It Matters: Hepatitis B is widespread in the country and can cause liver failure or cancer. The WHO recommends vaccination within 24 hours of birth; critics warn delaying the dose could expose babies to preventable infection and question the study’s consent and oversight safeguards.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
